Literature DB >> 16793811

Antiretroviral treatment of HIV infected adults.

Steven G Deeks1.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16793811      PMCID： PMC1482340          DOI： 10.1136/bmj.332.7556.1489

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  46 in total

1.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

2.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

3.  A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

Authors:  Milos Opravil; Bernard Hirschel; Adriano Lazzarin; Hansjakob Furrer; Jean-Philippe Chave; Sabine Yerly; Leslie R Bisset; Marek Fischer; Pietro Vernazza; Enos Bernasconi; Manuel Battegay; Bruno Ledergerber; Huldrych Günthard; Colin Howe; Rainer Weber; Luc Perrin
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

4.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Authors:  R S Hogg; B Yip; K J Chan; E Wood; K J Craib; M V O'Shaughnessy; J S Montaner
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

Review 5.  Adverse effects of antiretroviral therapy.

Authors:  A Carr; D A Cooper
Journal:  Lancet       Date:  2000-10-21       Impact factor: 79.321

6.  Metabolic effects of indinavir in healthy HIV-seronegative men.

Authors:  M A Noor; J C Lo; K Mulligan; J M Schwarz; R A Halvorsen; M Schambelan; C Grunfeld
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

7.  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Authors:  Joel E Gallant; Edwin DeJesus; José R Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

8.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

9.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

10.  Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Authors:  Motasim Badri; Douglas Wilson; Robin Wood
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321
View more
  16 in total

1.  Human health resources are key to HIV treatment in Africa.

Authors:  Ntambwe Malangu
Journal:  BMJ       Date:  2006-07-08

Review 2.  Selection of RNAi-based inhibitors for anti-HIV gene therapy.

Authors:  Stefanie A Knoepfel; Mireille Centlivre; Ying Poi Liu; Fatima Boutimah; Ben Berkhout
Journal:  World J Virol       Date:  2012-06-12

3.  Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.

Authors:  Touraj Farazmandfar; Mohammad Reza Haghshenas; Majid Shahbazi
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

4.  Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis.

Authors:  Ayman Bannaga; Omar Rahama; Gavin Barlow
Journal:  BMJ Case Rep       Date:  2013-04-25

5.  Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.

Authors:  Cissy Kityo; Stephanie Bousheri; Juliette Akao; Francis Ssali; Rose Byaruhanga; Isaac Ssewanyana; Prossy Muloma; Sula Myalo; Rose Magala; Yichen Lu; Peter Mugyenyi; Huyen Cao
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

6.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

Review 7.  Tipranavir: a review of its use in the management of HIV infection.

Authors:  Jennifer S Orman; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.

Authors:  David E Martin; Robert Blum; Judy Doto; Hal Galbraith; Charles Ballow
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

10.  Pharmacotherapy of pediatric and adolescent HIV infection.

Authors:  Susan J Schuval
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.